Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
OSI Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc.
Case Number:
1:09-cv-00185
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 02, 2012
Mylan Denied Invalidity In Cancer Drug IP Battle
A Delaware federal judge Tuesday found in favor of Genentech Inc., Pfizer Inc. and Astellas Pharma Inc. unit OSI Pharmaceuticals Inc. in their patent infringement suit against Mylan Pharmaceuticals Inc. over its generic version of the lung cancer drug Tarceva.
-
March 17, 2011
Teva Exits Astellas Patent Suit Over Cancer Drug
Astellas Pharma Inc. unit OSI Pharmaceuticals Inc., Genentech Inc. and Pfizer Inc. settled their infringement suit over generic versions of the cancer treatment Tarceva with Teva Pharmaceuticals USA Inc. in Delaware on Tuesday, leaving Mylan Pharmaceuticals Inc. as the sole defendant in the litigation.